Design of Nanoparticles for Immunotherapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biopharmaceutics".

Deadline for manuscript submissions: closed (10 October 2021) | Viewed by 4095

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biomedical Science and BK21 PLUS Center for Creative Biomedical Scientists at Chonnam National University, Chonnam National University Medical School, Gwangju 61469, Korea
Interests: nanoparticles mediated delivery of therapeutic drug and genes; bio-compatible hydrogels
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Agricultural Biotechnology, College of Agriculture and Life Sciences, Seoul National University, 1 Gwanangno, Gwanak-gu, Seoul 08826, Korea
Interests: nanoparticle; nanotechnology; adjuvant; nanovaccinology; polymeric vaccine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer and virus or bacteria infection are the leading causes of death globally. Even though chemotherapy is a commonly used therapeutic clinical strategy to treat the diseases, its effectiveness is limited due to a steep dose–response relationship, narrow therapeutic window, and non-specific organ toxicity. Therefore, there is a demand for developing more effective therapeutic strategies. Preclinical findings regarding adaptive immune therapy are very impressive, but little success has been obtained so far in translating effectively these results into the clinic. One major reason for this is the highly complex immune systems. The immune-suppressive properties of tumor and virus or bacteria infection prevent anti-immune effector cells from acting against related cells. Recent advances in science and technology have led to the development of a variety of delivery systems such as nanoparticles capable of generating robust balanced immune responses. These systems are responsive to variations in pH, redox potential, enzymatic activation, thermal gradients, magnetic fields, light, ultrasound and biological conditions. These systems can even be tailored to be responsive to dual or multiple stimuli. Topics of interest to this Special Issue include natural and biomimetic microenvironment-responsive particles for immunotherapy, anti-tumor immunity-eliciting nanoparticles, and related concepts.

 

Prof. Dr. In-Kyu Park
Prof. Dr. Chong-Su Cho
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Polymeric nanoparticles for immunotherapy
  • Tumor microenvironment-responsive immunotherapeutic nanoparticles
  • External and internal stimuli-responsive nanoparticles for immunotherapy
  • Combinational anti-cancer vaccine therapy and immunotherapy
  • Tumor microenvironment-remodeling immunotherapeutic nanoparticles

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

28 pages, 5048 KiB  
Review
Metallic Nanoparticle-Mediated Immune Cell Regulation and Advanced Cancer Immunotherapy
by Adityanarayan Mohapatra, Padmanaban Sathiyamoorthy and In-Kyu Park
Pharmaceutics 2021, 13(11), 1867; https://doi.org/10.3390/pharmaceutics13111867 - 4 Nov 2021
Cited by 20 | Viewed by 3516
Abstract
Cancer immunotherapy strategies leveraging the body’s own immune system against cancer cells have gained significant attention due to their remarkable therapeutic efficacy. Several immune therapies have been approved for clinical use while expanding the modalities of cancer therapy. However, they are still not [...] Read more.
Cancer immunotherapy strategies leveraging the body’s own immune system against cancer cells have gained significant attention due to their remarkable therapeutic efficacy. Several immune therapies have been approved for clinical use while expanding the modalities of cancer therapy. However, they are still not effective in a broad range of cancer patients because of the typical immunosuppressive microenvironment and limited antitumor immunity achieved with the current treatment. Novel approaches, such as nanoparticle-mediated cancer immunotherapies, are being developed to overcome these challenges. Various types of nanoparticles, including liposomal, polymeric, and metallic nanoparticles, are reported for the development of effective cancer therapeutics. Metallic nanoparticles (MNPs) are one of the promising candidates for anticancer therapy due to their unique theranostic properties and are thus explored as both imaging and therapeutic agents. In addition, MNPs offer a dense surface functionalization to target tumor tissue and deliver genetic, therapeutic, and immunomodulatory agents. Furthermore, MNPs interact with the tumor microenvironment (TME) and regulate the levels of tumor hypoxia, glutathione (GSH), and reactive oxygen species (ROS) for remodulation of TME for successful therapy. In this review, we discuss the role of nanoparticles in tumor microenvironment modulation and anticancer therapy. In particular, we evaluated the response of MNP-mediated immune cells, such as dendritic cells, macrophages, T cells and NK cells, against tumor cells and analyzed the role of MNP-based cancer therapies in regulating the immunosuppressive environment. Full article
(This article belongs to the Special Issue Design of Nanoparticles for Immunotherapy)
Show Figures

Figure 1

Back to TopTop